Thrombotic Events after COVID-19 Vaccination in the Over-50s: Results from a Population-Based Study in Italy

Several European countries suspended or changed recommendations for the use of Vaxzevria (AstraZeneca) for suspected adverse effects due to atypical blood-clotting. This research aims to identify a reference point towards the number of thrombotic events expected in the Italian population over 50 yea...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ileana Baldi, Danila Azzolina, Andrea Francavilla, Patrizia Bartolotta, Giulia Lorenzoni, Diego Vanuzzo, Dario Gregori
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	claims data COVID-19 Vaxzevria safety adverse events Italy Medicine R
Acceso en línea:	https://doaj.org/article/c14df2f6ff054b3c9cbd83ad24e09c6d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c14df2f6ff054b3c9cbd83ad24e09c6d
record_format	dspace
spelling	oai:doaj.org-article:c14df2f6ff054b3c9cbd83ad24e09c6d2021-11-25T19:11:10ZThrombotic Events after COVID-19 Vaccination in the Over-50s: Results from a Population-Based Study in Italy10.3390/vaccines91113072076-393Xhttps://doaj.org/article/c14df2f6ff054b3c9cbd83ad24e09c6d2021-11-01T00:00:00Zhttps://www.mdpi.com/2076-393X/9/11/1307https://doaj.org/toc/2076-393XSeveral European countries suspended or changed recommendations for the use of Vaxzevria (AstraZeneca) for suspected adverse effects due to atypical blood-clotting. This research aims to identify a reference point towards the number of thrombotic events expected in the Italian population over 50 years of age who received Vaxzevria from 22 January to 12 April 2021. The venous thromboembolism (VT) and immune thrombocytopenia (ITP) event rates were estimated from a population-based cohort. The overall VT rate was 1.15 (95% CI 0.93–1.42) per 1000 person-years, and the ITP rate was 2.7 (95% CI 0.7–11) per 100,000 person-years. These figures translate into 83 and two expected events of VT and ITP, respectively, in the 15 days following the first administration of Vaxzevria. The number of thrombotic events reported from the Italian Medicines Agency does not appear to have increased beyond that expected in individuals over 50 years of age.Ileana BaldiDanila AzzolinaAndrea FrancavillaPatrizia BartolottaGiulia LorenzoniDiego VanuzzoDario GregoriMDPI AGarticleclaims dataCOVID-19Vaxzevriasafetyadverse eventsItalyMedicineRENVaccines, Vol 9, Iss 1307, p 1307 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	claims data COVID-19 Vaxzevria safety adverse events Italy Medicine R
spellingShingle	claims data COVID-19 Vaxzevria safety adverse events Italy Medicine R Ileana Baldi Danila Azzolina Andrea Francavilla Patrizia Bartolotta Giulia Lorenzoni Diego Vanuzzo Dario Gregori Thrombotic Events after COVID-19 Vaccination in the Over-50s: Results from a Population-Based Study in Italy
description	Several European countries suspended or changed recommendations for the use of Vaxzevria (AstraZeneca) for suspected adverse effects due to atypical blood-clotting. This research aims to identify a reference point towards the number of thrombotic events expected in the Italian population over 50 years of age who received Vaxzevria from 22 January to 12 April 2021. The venous thromboembolism (VT) and immune thrombocytopenia (ITP) event rates were estimated from a population-based cohort. The overall VT rate was 1.15 (95% CI 0.93–1.42) per 1000 person-years, and the ITP rate was 2.7 (95% CI 0.7–11) per 100,000 person-years. These figures translate into 83 and two expected events of VT and ITP, respectively, in the 15 days following the first administration of Vaxzevria. The number of thrombotic events reported from the Italian Medicines Agency does not appear to have increased beyond that expected in individuals over 50 years of age.
format	article
author	Ileana Baldi Danila Azzolina Andrea Francavilla Patrizia Bartolotta Giulia Lorenzoni Diego Vanuzzo Dario Gregori
author_facet	Ileana Baldi Danila Azzolina Andrea Francavilla Patrizia Bartolotta Giulia Lorenzoni Diego Vanuzzo Dario Gregori
author_sort	Ileana Baldi
title	Thrombotic Events after COVID-19 Vaccination in the Over-50s: Results from a Population-Based Study in Italy
title_short	Thrombotic Events after COVID-19 Vaccination in the Over-50s: Results from a Population-Based Study in Italy
title_full	Thrombotic Events after COVID-19 Vaccination in the Over-50s: Results from a Population-Based Study in Italy
title_fullStr	Thrombotic Events after COVID-19 Vaccination in the Over-50s: Results from a Population-Based Study in Italy
title_full_unstemmed	Thrombotic Events after COVID-19 Vaccination in the Over-50s: Results from a Population-Based Study in Italy
title_sort	thrombotic events after covid-19 vaccination in the over-50s: results from a population-based study in italy
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/c14df2f6ff054b3c9cbd83ad24e09c6d
work_keys_str_mv	AT ileanabaldi thromboticeventsaftercovid19vaccinationintheover50sresultsfromapopulationbasedstudyinitaly AT danilaazzolina thromboticeventsaftercovid19vaccinationintheover50sresultsfromapopulationbasedstudyinitaly AT andreafrancavilla thromboticeventsaftercovid19vaccinationintheover50sresultsfromapopulationbasedstudyinitaly AT patriziabartolotta thromboticeventsaftercovid19vaccinationintheover50sresultsfromapopulationbasedstudyinitaly AT giulialorenzoni thromboticeventsaftercovid19vaccinationintheover50sresultsfromapopulationbasedstudyinitaly AT diegovanuzzo thromboticeventsaftercovid19vaccinationintheover50sresultsfromapopulationbasedstudyinitaly AT dariogregori thromboticeventsaftercovid19vaccinationintheover50sresultsfromapopulationbasedstudyinitaly
_version_	1718410240345505792

Thrombotic Events after COVID-19 Vaccination in the Over-50s: Results from a Population-Based Study in Italy

Ejemplares similares